TSE:MDP FY2028 EPS Estimate Lifted by Leede Financial

Medexus Pharmaceuticals Inc. (TSE:MDP) – Leede Financial increased their FY2028 earnings estimates for shares of Medexus Pharmaceuticals in a research report issued on Monday, December 2nd. Leede Financial analyst D. Loe now expects that the company will earn $1.15 per share for the year, up from their prior forecast of $1.14. Leede Financial has a “Speculative Buy” rating and a $8.25 price target on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share.

Several other equities analysts have also recently issued reports on the stock. Raymond James upgraded shares of Medexus Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their price target for the company from C$3.00 to C$4.00 in a research report on Wednesday, November 20th. Stifel Canada raised shares of Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a research note on Monday, August 12th. Finally, Stifel Nicolaus upped their price objective on shares of Medexus Pharmaceuticals from C$3.00 to C$3.50 and gave the company a “buy” rating in a research note on Thursday, August 22nd. Three equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Medexus Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of C$5.25.

Medexus Pharmaceuticals Stock Performance

Shares of TSE MDP opened at C$2.80 on Tuesday. Medexus Pharmaceuticals has a 52-week low of C$1.44 and a 52-week high of C$3.16. The firm has a 50 day moving average price of C$2.47 and a two-hundred day moving average price of C$2.25. The stock has a market cap of C$68.68 million, a P/E ratio of 56.00 and a beta of 1.96.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.